Human NFKB1/KBF1/ EBP-1 ORF/cDNA clone-Adenovirus plasmid (BC051765)
Pre-made Human NFKB1/KBF1/ EBP-1 adenoviral expression plasmid for NFKB1 adenovirus packaging, NFKB1 adenovirus.
Our GM-Adenovirus vector is optimized with the GMVC-modified Adeasy adenovirus packaging system. Find more about the GMVC-modified adenovirus packaging system.
Go
to p105/NFKB1/KBF1 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Plasmid Grade | Plasmid quantity |
---|---|---|---|
pGMAP000579 | 0 Adenovirus plasmid | Research Grade | 10mg, 50mg, 100mg, 500mg, >1g |
GMP-like Grade | 10mg, 50mg, 100mg, 500mg, >1g | ||
High Quality (HQ) Grade | |||
Seed | 5ug |
Product Description
Catalog ID | pGMAP000579 |
Gene Name | NFKB1 |
Accession Number | BC051765 |
Gene ID | 4790 |
Species | Human |
Product Type | Adenovirus plasmid (overexpression) |
Insert Length | 3896 bp |
Gene Alias | KBF1, EBP-1, NF-kB, CVID12, NF-kB1, NFKB-p50, NFkappaB, NF-kappaB, NFKB-p105, NF-kappa-B1, NF-kappabeta |
Fluorescent Reporter | ZsGreen |
Mammalian Cell Selection | Puromyocin |
Fusion Tag | 3xflag (C-Terminal) |
Promoter | CMV |
Resistance | Amplicin |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
---|---|---|
Target Antibody | GM-Tg-g-T40192-Ab | Anti-p105 monoclonal antibody |
Target Antigen | GM-Tg-g-T40192-Ag | p105/NFKB1 protein |
ORF Viral Vector | pGMLV002079 | Human NFKB1 Lentivirus plasmid |
ORF Viral Vector | pGMPC000683 | Human NFKB1 Mammalian (Non-Viral Vector) plasmid |
ORF Viral Vector | pGMAP000579 | 0 Adenovirus plasmid |
ORF Viral Vector | vGMLV002079 | Human NFKB1 Lentivirus particle |
Target information
Target ID | GM-T40192 |
Target Name | p105 |
Gene ID | 4790, 18033, 710324, 81736, 100142683, 442859, 616115, 100067894 |
Gene Symbol and Synonyms | CVID12,EBP-1,KBF1,NF-kappa-B1,NF-kappaB,NF-kappaB1,NF-kappabeta,NF-kB,NF-kB1,NFkappaB,NFKB-p105,NFKB-p50,NFKB1,p105,p50,p50/p105 |
Uniprot Accession | P19838 |
Uniprot Entry Name | NFKB1_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target |
Disease | Cancer |
Gene Ensembl | ENSG00000109320 |
Target Classification | Tumor-associated antigen (TAA) |
This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. NFKB is a critical regulator of the immediate-early response to viral infection. Alternative splicing results in multiple transcript variants encoding different isoforms, at least one of which is proteolytically processed. [provided by RefSeq, Aug 2020]
About GMVC
GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.